 |
4 Products |  |
0 Diseases | | 4 Products |
|
6 Trials |  |
193 News |  |
| 12» |
- || Review, Journal: CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting. (Pubmed Central) - Jul 14, 2025
By integrating structural insights with translational drug development, this review provides a framework for optimizing CD28- and ICOS-targeted therapies. Further advancements in biologics, peptide-based inhibitors, and immune checkpoint modulation will enhance the precision and efficacy of immunotherapeutic strategies.
- vopratelimab (JTX-2011) / Concentra Biosci
Trial termination: Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - May 29, 2024
P1/2, N=4, Terminated, Sponsor: Jounce Therapeutics, Inc.
Further advancements in biologics, peptide-based inhibitors, and immune checkpoint modulation will enhance the precision and efficacy of immunotherapeutic strategies. Completed --> Terminated; Sponsor decision to discontinue providing study drug to patients who have been on study treatment for more than two years
- ||||| vopratelimab (JTX-2011) / Concentra, pimivalimab (JTX-4014) / Concentra
Trial termination: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov) - May 22, 2024
P2, N=69, Terminated, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Terminated; The Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.
- polzastobart (JTX-8064) / Concentra, pimivalimab (JTX-4014) / Concentra
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) (Hall A; Poster Bd #: 226) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1697;
P1/2
Treatment was reasonably well-tolerated. Identification & evaluation of clinical and molecular phenotypes most likely to benefit from LILRB2-targeted therapies are warranted.
- vopratelimab (JTX-2011) / Concentra
Oral Abstract - ICOS Agonist Vopratelimab Modulates Follicular Helper T Cells and Improves B Cell Function in Common Variable Immunodeficiency () - Apr 19, 2024 - Abstract #CIS2024CIS_294;
- ||| THE-630 / Concentra Biosci
Trial termination, Stroma, Metastases: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Apr 12, 2024
P1/2, N=32, Terminated, Sponsor: Theseus Pharmaceuticals
Identification & evaluation of clinical and molecular phenotypes most likely to benefit from LILRB2-targeted therapies are warranted. Active, not recruiting --> Terminated; The Sponsor terminated the study due to early dose-limiting toxicities.
- || vopratelimab (JTX-2011) / Concentra, pimivalimab (JTX-4014) / Concentra
Biomarker, Trial primary completion date, Combination therapy, IO biomarker, Metastases: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov) - Mar 11, 2024
P2, N=69, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Terminated; The Sponsor terminated the study due to early dose-limiting toxicities. Trial primary completion date: Sep 2022 --> May 2024
- ||| polzastobart (JTX-8064) / Concentra Biosci
Trial completion, Enrollment change, Combination therapy, Monotherapy, Metastases: INNATE: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Feb 12, 2024
P1/2, N=190, Completed, Sponsor: Jounce Therapeutics, Inc.
Trial primary completion date: Sep 2022 --> May 2024 Active, not recruiting --> Completed | N=281 --> 190
- | vopratelimab (JTX-2011) / Concentra, carboplatin / Generic mfg.
Journal, IO biomarker: Analysis and Regulatory Mechanisms of Platelet-Related Genes in Patients with Ischemic Stroke. (Pubmed Central) - Jan 8, 2024
In addition, Caffeine, Carboplatin, and Vopratelimab were the targeted drugs of these key genes. This study identified four platelet-related key genes of IS, which might help to deepen the understanding of the role of platelet-related genes in the molecular mechanism of IS.
- ||| THE-630 / Concentra Biosci
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Stroma, Metastases: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Jul 31, 2023
P1/2, N=32, Active, not recruiting, Sponsor: Theseus Pharmaceuticals
This study identified four platelet-related key genes of IS, which might help to deepen the understanding of the role of platelet-related genes in the molecular mechanism of IS. Recruiting --> Active, not recruiting | N=160 --> 32 | Trial completion date: Jun 2026 --> Feb 2024 | Trial primary completion date: Jun 2025 --> Feb 2024
- | vopratelimab (JTX-2011) / Concentra, pimivalimab (JTX-4014) / Concentra
Biomarker, Trial completion date, Combination therapy, IO biomarker, Metastases: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov) - Jul 3, 2023
P2, N=69, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=160 --> 32 | Trial completion date: Jun 2026 --> Feb 2024 | Trial primary completion date: Jun 2025 --> Feb 2024 Trial completion date: Mar 2023 --> May 2024
- || pimivalimab (JTX-4014) / Concentra
Trial completion, Trial completion date, Metastases: Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (clinicaltrials.gov) - May 3, 2023
P1, N=18, Completed, Sponsor: Jounce Therapeutics, Inc.
Trial completion date: Mar 2023 --> May 2024 Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Feb 2023
- vopratelimab (JTX-2011) / Concentra Biosci
Trial completion, Trial completion date, Trial primary completion date: Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - May 1, 2023
P1/2, N=4, Completed, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Feb 2023 Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jan 2023 | Trial primary completion date: Apr 2024 --> Jan 2023
- ||| polzastobart (JTX-8064) / Concentra Biosci
Enrollment closed, Combination therapy, Monotherapy, Metastases: INNATE: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=281, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jan 2023 | Trial primary completion date: Apr 2024 --> Jan 2023 Recruiting --> Active, not recruiting
- | polzastobart (JTX-8064) / Jounce Therap
Journal, PD(L)-1 Biomarker, IO biomarker: Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. (Pubmed Central) - Apr 4, 2023
In a human tumor explant culture, pharmacodynamic activity of JTX-8064 was observed in monotherapy and in combination with anti-PD-1. Collectively, our work provides strong translational and pre-clinical rationale to target LILRB2 in cancer.
- vopratelimab (JTX-2011) / Jounce Therap, pimivalimab (JTX-4014) / Jounce Therap
SELECT: A phase 2 randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts) (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_334;
P2
P is active and continues to be used in combination trials. Shorter TE duration of V 0.03 mg/kg may contribute to clinical activity.
- JTX-8064 / Jounce Therap, pimivalimab (JTX-4014) / Jounce Therap
Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_325;
P1/2
Conclusions JTX-8064 was well-tolerated as mono and with pimi, with 700 mg q3w selected as the preliminary RP2D. Enrollment is ongoing in P2, including cohorts in renal and ovarian cancer that have met Simon's 2-stage response criteria to expand.
- JTX-1484 / Jounce Therap
Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_818;
Ethics Approval Human blood and tumor samples were acquired from commercial providers and from the CHTN and NDRI networks respectively. Specimens were collected under each provider's human subject research institutional review board approved protocols and were fully anonymized or otherwise permanently de-identified to recipient investigators.
- || vopratelimab (JTX-2011) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker: First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response. (Pubmed Central) - Sep 10, 2022
Efficacy was observed only in a subset of patients with a vopratelimab-specific pharmacodynamic biomarker. A potential predictive biomarker of response was identified, which is being prospectively evaluated in a randomized Phase 2 non-small cell lung cancer trial.
- | vopratelimab (JTX-2011) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Agonizing over the stimulatory immune checkpoint ICOS. (Pubmed Central) - Sep 10, 2022
Nevertheless, T-cell agonists as cancer immunotherapies continue to be challenging. See related article by Yap et al., p. 3695.
- || pimivalimab (JTX-4014) / Concentra
Enrollment change, Trial completion date, Metastases: Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (clinicaltrials.gov) - Sep 10, 2022
P1, N=18, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
See related article by Yap et al., p. 3695. N=40 --> 18 | Trial completion date: Aug 2022 --> Aug 2023
- ||| vopratelimab (JTX-2011) / Concentra Biosci
Enrollment closed, Enrollment change: Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - Sep 10, 2022
P1/2, N=4, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
N=40 --> 18 | Trial completion date: Aug 2022 --> Aug 2023 Recruiting --> Active, not recruiting | N=20 --> 4
- ||| vopratelimab (JTX-2011) / Concentra
Trial completion, Enrollment change, Trial completion date: EMERGE: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (clinicaltrials.gov) - Sep 10, 2022
P2, N=61, Completed, Sponsor: Jounce Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=20 --> 4 Active, not recruiting --> Completed | N=452 --> 61 | Trial completion date: Jul 2022 --> Mar 2022
- || vopratelimab (JTX-2011) / Jounce Therap, izuralimab (XmAb23104) / Xencor
The sun sets on #Icos (via @JacobPlieth) https://t.co/w4C44YkWk5 #vopratelimab #Izuralimab $JNCE $XNCR $AZN $BMY $GSK (Twitter) - Aug 31, 2022
- |||||| vopratelimab (JTX-2011) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Clinical, IO biomarker: #Vopratelimab, an ICOS agonist #MonoclonalAntibody, is safe alone and with #nivolumab with antitumor activity in #SolidTumor patients expressing a vopratelimab-specific biomarker. https://t.co/WQXEkL2aQm @JustinGainor @RPachynski @HaeseongPark1 (Twitter) - Jun 15, 2022
- || vopratelimab (JTX-2011) / Concentra, pimivalimab (JTX-4014) / Concentra
Biomarker, Enrollment closed, Trial primary completion date, Combination therapy, IO biomarker, Metastases: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov) - May 18, 2022
P2, N=75, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Completed | N=452 --> 61 | Trial completion date: Jul 2022 --> Mar 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Sep 2022
- | polzastobart (JTX-8064) / Concentra Biosci
Phase classification, Combination therapy, Monotherapy, Metastases: INNATE: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Jan 6, 2022
P1/2, N=281, Recruiting, Sponsor: Jounce Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Sep 2022 Phase classification: P1 --> P1/2
- ||| THE-630 / Concentra Biosci
Enrollment open, Stroma, Metastases: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Dec 27, 2021
P1/2, N=160, Recruiting, Sponsor: Theseus Pharmaceuticals
Phase classification: P1 --> P1/2 Not yet recruiting --> Recruiting
- | THE-630 / Concentra Biosci
New P1/2 trial, Stroma, Metastases: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Dec 15, 2021
P1/2, N=160, Not yet recruiting, Sponsor: Theseus Pharmaceuticals
- || polzastobart (JTX-8064) / Concentra Biosci
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: INNATE: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Aug 18, 2021
P1, N=281, Recruiting, Sponsor: Jounce Therapeutics, Inc.
Not yet recruiting --> Recruiting N=40 --> 281 | Trial completion date: Sep 2022 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Sep 2023
- | pimivalimab (JTX-4014) / Concentra
Trial completion date, Metastases: Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (clinicaltrials.gov) - May 17, 2021
P1, N=40, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
N=40 --> 281 | Trial completion date: Sep 2022 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Sep 2023 Trial completion date: May 2021 --> Aug 2022
- Keytruda (pembrolizumab) / Merck (MSD), pimivalimab (JTX-4014) / Jounce Therap
[VIRTUAL] Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2729;
P1
INNATE will assess pharmacodynamic and potential predictive biomarkers of response, and the expansion cohorts will explore multiple patient populations, including PD-(L)1i sensitive and PD-(L)1i-resistant (primary or acquired) patients to address current unmet medical needs . Enrolment in INNATE began in January 2021.
- vopratelimab (JTX-2011) / Jounce Therap, pimivalimab (JTX-4014) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1110;
P2
Secondary endpoints include ORR and PFS according to RECIST v1.1, OS, safety, and association of baseline TIS score with clinical outcomes . The study has a target enrollment goal of approximately 75 patients; the first patient was dosed October 2020.
- JTX-8064 / Jounce Therap
[VIRTUAL] Tumor associated macrophages and resistance to immune checkpoint blockade: consideration of cancer indications for the clinical development of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody () - Mar 11, 2021 - Abstract #AACR2021AACR_1274;
The activities of JTX-8064 in cell culture and high LILRB2 expression in non-responding patients with high levels of IFNg signature expression provides a rationale that JTX-8064 may be able to overcome anti-PD-1 primary resistance mechanisms. JTX-8064 is currently in Phase 1 clinical development as a monotherapy and combination with anti-PD-1 inhibitors in settings with both anti-PD-1(L1) naïve and anti-PD-1(L1) experienced patients in specific cancer types.
- || pimivalimab (JTX-4014) / Jounce Therap
Clinical, P1 data, Journal: Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors. (Pubmed Central) - Mar 9, 2021
P1
JTX-8064 is currently in Phase 1 clinical development as a monotherapy and combination with anti-PD-1 inhibitors in settings with both anti-PD-1(L1) naïve and anti-PD-1(L1) experienced patients in specific cancer types. Further development of JTX-4014 is warranted as a monotherapy or in combination with other innovative cancer therapies.
- JTX-8064 / Jounce Therap
[VIRTUAL] Evaluating Biomarkers of JTX-8064 (Anti-LILRB2/ILT4 Monoclonal Antibody) to Inform Clinical Development () - Feb 17, 2021 - Abstract #TRICON2021TRICON_217;
Using histoculture, pharmacodynamic (PD) responses to JTX-8064 can be measured preclinically in a human ex vivo tumor system. Ex vivo evaluation of human tumors identified hypotheses for both predictive and pharmacodynamic markers that can be evaluated in the clinical development of JTX-8064.
- ||| vopratelimab (JTX-2011) / Concentra
Enrollment closed: EMERGE: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (clinicaltrials.gov) - Jan 11, 2021
P2, N=452, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Ex vivo evaluation of human tumors identified hypotheses for both predictive and pharmacodynamic markers that can be evaluated in the clinical development of JTX-8064. Recruiting --> Active, not recruiting
- || polzastobart (JTX-8064) / Concentra Biosci
New P1 trial, Combination therapy, Monotherapy, Metastases: INNATE: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov) - Dec 16, 2020
P1, N=40, Recruiting, Sponsor: Jounce Therapeutics, Inc.
- | vopratelimab (JTX-2011) / Jounce Therap
Preclinical, Journal: ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. (Pubmed Central) - Nov 18, 2020
Additional benefit is observed when the ICOS antibodies are administered in combination with anti-PD-1 and anti-CTLA-4 therapies. Based on the preclinical data, JTX-2011 is currently being developed in the clinical setting for the treatment of solid tumors.
- JTX-8064 / Jounce Therap
[VIRTUAL] Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development () - Oct 14, 2020 - Abstract #SITC2020SITC_1253;
Further bioinformatics analysis revealed additional cancer subtypes where these biomarkers are enriched. Conclusions These data will inform indication selection and combination strategies for JTX-8064 to maximize potential therapeutic benefit for patients with solid tumor malignancies.
- JTX-8064 / Jounce Therap
[VIRTUAL] Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development () - Oct 14, 2020 - Abstract #SITC2020SITC_518;
Further bioinformatics analysis revealed additional cancer subtypes where these biomarkers are enriched. Conclusions These data will inform indication selection and combination strategies for JTX-8064 to maximize potential therapeutic benefit for patients with solid tumor malignancies.
- |||| vopratelimab (JTX-2011) / Concentra, pimivalimab (JTX-4014) / Concentra
Biomarker, New P2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov) - Sep 14, 2020
P2, N=75, Recruiting, Sponsor: Jounce Therapeutics, Inc.
- vopratelimab (JTX-2011) / Jounce Therap
[VIRTUAL] Reverse Translational Approaches in Development of ICOS Agonist Vopratelimab () - Aug 31, 2020 - Abstract #PEGS2020PEGS_281;
In the ICONIC trial, emergence of these cells was associated with improved ORR, PFS, and OS. An RNA signature in baseline tumor samples appears to predict for emergence of ICOS high CD4 T cells and improved clinical outcomes.
- |||| vopratelimab (JTX-2011) / Concentra Biosci
Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: ICONIC: JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - Aug 21, 2020
P1/2, N=242, Completed, Sponsor: Jounce Therapeutics, Inc.
An RNA signature in baseline tumor samples appears to predict for emergence of ICOS high CD4 T cells and improved clinical outcomes. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2020 | Trial primary completion date: Dec 2020 --> Jun 2020
- | pimivalimab (JTX-4014) / Concentra
Trial completion date, Metastases: Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies (clinicaltrials.gov) - May 28, 2020
P1, N=40, Active, not recruiting, Sponsor: Jounce Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2020 | Trial primary completion date: Dec 2020 --> Jun 2020 Trial completion date: Dec 2020 --> May 2021
- vopratelimab (JTX-2011) / Jounce Therap
ICOS hi CD4 T cells emerging on vopratelimab treatment have Th1 central memory characteristics and may contribute to durability of clinical responses (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_261;
P1/2, P2
Transcriptional profiling of ICOS hi CD4 T cells further defined the phenotype as Tcm cells that express cytotoxic effector molecules, which may contribute to observed clinical benefit. Treatment with ipi in combination with an ICOS agonist resulted in enhanced efficacy in mice, and follow-up studies exploring sequential dosing are ongoing.
- || vopratelimab (JTX-2011) / Concentra Biosci
New P1/2 trial: Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - Mar 24, 2020
P1/2, N=20, Recruiting, Sponsor: Jounce Therapeutics, Inc.
- vopratelimab (JTX-2011) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial. (Gatlin Ballroom B, Level 1 - Poster Board B8) - Dec 17, 2019 - Abstract #ASCOSITC2020ASCO_SITC_224;
P1/2
Clinical evaluation of vopra and investigational PD-1 inhibitor JTX-4014 in cancer patients with RS selection is planned. Research Funding: Jounce Therapeutics.
- vopratelimab (JTX-2011) / Jounce Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial. (Gatlin Ballroom B, Level 1 - Poster Board B8) - Dec 17, 2019 - Abstract #ASCOSITC2020ASCO_SITC_133;
P1/2
Clinical evaluation of vopra and investigational PD-1 inhibitor JTX-4014 in cancer patients with RS selection is planned. Research Funding: Jounce Therapeutics.
- ||| vopratelimab (JTX-2011) / Concentra
Enrollment change: EMERGE: Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (clinicaltrials.gov) - Nov 15, 2019
P2, N=452, Recruiting, Sponsor: Jounce Therapeutics, Inc.
Research Funding: Jounce Therapeutics. N=226 --> 452